Entrada Therapeutics, Inc. (TRDA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV) therapeutics to target intracellular diseases. The company focuses primarily on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $1.95 million | $94.69 million | $22.51 million | $153.81 million |
| Net Loss | $(43.10) million | $55.03 million (Income) | $(60.45) million | $78.53 million (Income) |
| Operating Expenses | $48.80 million | $41.27 million | $91.15 million | $79.28 million |
| Cash & Cash Equivalents | $72.48 million | $101.21 million | $72.48 million | $101.21 million |
| Marketable Securities | $281.53 million | $318.79 million | $281.53 million | $318.79 million |
| Total Liquidity | $354.01 million | $419.99 million | $354.01 million | $419.99 million |
Note: The filing does not provide specific gross margin data as the company has no product sales revenue. Operating loss margins are not applicable due to the lack of product revenue.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped significantly from $94.7 million in Q2 2024 to $2.0 million in Q2 2025. This decrease is primarily due to the substantial completion of research plan activities for the partnered candidate VX-670 under the Vertex Agreement during Q1 2025, resulting in fewer cost reimbursements and deferred revenue recognition.
- Profitability Shift: The company swung from a net income of $55.0 million in Q2 2024 to a net loss of $43.1 million in Q2 2025. The prior year's income was driven by a $75 million clinical advancement milestone recognized in Q1 2024.
- Expense Increase: Operating expenses increased by $7.5 million year-over-year for the quarter. Research and Development (R&D) expenses rose by $5.8 million, driven by increased personnel costs (including $1.7 million in severance from a workforce reduction) and progress on DMD programs.
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased by approximately $66 million from the prior year period, reflecting operating cash burn and lower revenue recognition.
Guidance, Outlook, and Risks
- Strategic Plan & Workforce Reduction: In April 2025, the company announced a strategic plan to focus resources on DMD clinical candidates and key preclinical programs. This included a ~20% workforce reduction, incurring a one-time charge of $1.9 million ($1.7M R&D, $0.2M G&A).
- Clinical Pipeline Updates:
- ENTR-601-44: First patient dosed in the global Phase 1/2 MAD trial (ELEVATE-44-201). Data expected H1 2026.
- ENTR-601-45: Initiated global Phase 1/2 MAD trial (ELEVATE-45-201). First patient dosing expected Q3 2025.
- ENTR-601-50: Regulatory application submission expected Q4 2025.
- VX-670 (Vertex): Partner is enrolling in Phase 1/2 MAD trial for DM1; completion expected H1 2026.
- Liquidity Outlook: Management believes current resources of $354.0 million are sufficient to fund operations into the second quarter of 2027.
- Risks & Contingencies:
- Legal Proceedings: Ohio State Innovation Foundation (OSIF) filed a complaint in February 2025 alleging breach of contract regarding sublicensing fees. The company disputes the claims.
- Regulatory & Development: Risks include the unproven nature of the EEV platform, potential clinical trial failures, and reliance on third-party manufacturers.
- Capital Needs: The company will require additional financing to achieve its goals beyond 2027.
Investor Verification Checklist
- Vertex Revenue Run Rate: Verify the sustainability of collaboration revenue post-VX-670 research plan completion and the timeline for future milestone payments.
- Cash Burn Rate: Assess the monthly operating cash burn against the $354 million liquidity runway to confirm the Q2 2027 funding horizon.
- OSIF Litigation: Monitor the status of the Ohio State Innovation Foundation lawsuit and potential financial exposure regarding sublicensing fees.
- Clinical Milestones: Track the initiation of the ENTR-601-45 trial (Q3 2025) and the submission of the ENTR-601-50 application (Q4 2025) as key value drivers.
- Workforce Reduction Impact: Evaluate whether the 20% reduction in force achieves the anticipated cost savings without disrupting clinical trial execution.